Skip to main content
Evidence Snapshot

CD4+ve Th

CHEMBL613544 CELL-LINE
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613544
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats CD4+ve Th as ChEMBL target CHEMBL613544. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
CD4+ve Th
CELL-LINE
As of 2026-09-13
ChEMBL target ID
CHEMBL613544
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why CD4+ve Th matters

As of 2026-09-13

CD4+ve Th is reviewed as CD4+ve Th; the current evidence base includes 3 approved drugs, 49 compounds, and 56 assays, with lead potency reaching pChEMBL 10.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 49 compounds, and 56 assays for this target. The dominant activity type is IC50. CHEMBL269732 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL269732 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why CD4+ve Th matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

49
Total Compounds
56
Total Assays
3
Approved Drugs
IC50: 5.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL269732
 10.5 IC50 Approved
No preferred name
CHEMBL4085457
 7.3 IC50 Approved
No preferred name
CHEMBL4877265
 5.4 IC50 —
No preferred name
CHEMBL259571
 5.3 IC50 Approved
No preferred name
CHEMBL4876168
 5.1 IC50 —

Approved Drugs

Structure Compound First Approval
RITLECITINIB
CHEMBL4085457
 2023
TACROLIMUS ANHYDROUS
CHEMBL269732
 1994
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613544